Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study

3/20 Late treatment study

Mahajan et al., Indian Journal of Anasthesia, doi:10.4103/ija.IJA_149_21 (Peer Reviewed)
Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study

Source PDF Share Tweet

Small RCT with 34 remdesivir patients and 36 controls finding no significant difference in clinical outcomes.

Mahajan et al., 3/20/2021, Randomized Controlled Trial, India, South Asia, peer-reviewed, 3 authors.

risk of death, 76.5% higher, RR 1.76, p = 0.47, treatment 5 of 34 (14.7%), control 3 of 36 (8.3%).

risk of mechanical ventilation, 111.8% higher, RR 2.12, p = 0.42, treatment 4 of 34 (11.8%), control 2 of 36 (5.6%).

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.

All 29 studies All Outcomes

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit